Skip to main content

Table 2 Univariate analysis of CRRT group and non-CRRT group

From: The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study

Variable

CRRT (n = 142)

non-CRRT (n = 45)

P

General condition

 Age (years), median (IQR)

71 (61.5, 74.5)

68 (62, 76)

0.431

 The male, n (%)

77 (54.22%)

42 (93.33%)

0.158

 BMI, mean (SD)

24.56 (4.82)

25.00 (4.26)

0.760

 Temperature (℃), median (IQR)

36.7 (36.4, 37.7)

37.2 (36.5, 37.7)

0.746

 Heart rate, mean (SD)

108 (19)

99 (24)

0.151

 Breathing, median (IQR)

19 (15, 22)

20 (18, 21)

0.744

 MAP (mmHg), mean (SD)

83.24 (10.17)

81.86 (8.68)

0.648

 Baseline Scr (μmol/L), median (IQR)

67.4 (52.6, 82.25)

73.6 (50.8, 81.4)

0.867

Reason for ICU admission, n (%)

 Respiratory failure

64 (45.07%)

22 (48.89%)

0.654

 Circulatory failure

43 (30.28%)

12 (26.67%)

0.643

 Neurological diseases

20 (14.08%)

6 (13.33%)

0.899

 Trauma

6 (4.23%)

2 (4.44%)

0.950

 Others

9 (6.34%)

3 (6.67%)

0.938

Previous medical history, n (%)

 Hypertension

66 (46.48%)

22 (48.88%)

0.778

 Diabetes

28 (19.72%)

9 (20.00%)

0.967

 Ischemic heart disease

21 (14.79%)

8 (17.77%)

0.629

 Cerebrovascular disease

38 (26.76%)

15 (33.33%)

0.394

 Chronic liver disease

3 (2.11%)

1 (2.22%)

1.000

 Malignancy

60 (42.25%)

17 (37.78%)

0.595

Laboratory examination

 WBC (109/L), mean (SD)

17.87 (10.53)

17.63 (12.73)

0.945

 PLT (109/L), median (IQR)

130 (84.25, 229.75)

247.5 (141.25, 367)

0.040

 PCT (ng/ml), median (IQR)

7.42 (2.83, 20.81)

2.98 (0.97, 8.69)

0.045

 Scr (μmol/L), median (IQR)

267.35 (196.8, 358.52)

100.55 (64.87, 165.2)

0.000

 BUN (mmol/L), median (IQR)

18.36 (11.57, 29)

9.2 (6.72, 19.06)

0.009

 Total bilirubin (μmol/L), median (IQR)

19.2 (9.1, 46.5)

16.1 (9.75, 34.97)

0.635

 Lactate (mmol/L), median (IQR)

1.95 (1.32, 5.47)

1.75 (1.27, 2.22)

0.127

 Plasma NGAL (ng/ml), median (IQR)

297.13 (174.79, 485.57)

131.45 (87.36, 200.3)

0.000

 pH, mean (SD)

7.32 (0.11)

7.39 (0.06)

0.028

 Potassium concentration (mmol/L), median (IQR)

4.46 (4.13, 5.32)

4.3 (3.63, 4.54)

0.074

 Bicarbonate (mmol/L), median (IQR)

19.1 (14, 21.65)

20.8 (19.8, 24.2)

0.088

Stage of AKI, n (%)

 Stage 1, n (%)

16 (11.27%)

33 (73.33%)

0.000

 Stage 2, n (%)

33 (23.24%)

3 (6.67%)

0.014

 Stage 3, n (%)

93 (65.49%)

9 (20.00%)

0.000

Others

 FST 2 h urine output (ml), median (IQR)

35 (5, 143.75)

400 (210, 890)

0.000

 RRI, mean (SD)

0.68 (0.08)

0.63 (0.08)

0.072

 CVP (mmHg), median (IQR)

9 (8, 11)

9 (8, 11)

0.908

 Mechanical ventilation, n (%)

98 (69.01%)

28 (62.22%)

0.397

 Sepsis, n (%)

84 (59.15%)

23 (51.11%)

0.342

 SOFA score, mean (SD)

10.13 (3.18)

5.86 (2.72)

0.000

 APACHE II score, median (IQR)

22.5 (16, 29.5)

16 (15, 18)

0.006

  1. BMI, body mass index; WBC, white blood cell; PLT, platelet; PCT, procalcitonin; Scr, serum creatinine; BUN, blood urea nitrogen; NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute kidney injury; RRI, renal resistance index; CRRT, continuous renal replacement therapy; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II